In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Debiopharm S.A.

http://www.debiopharm.com/

Latest From Debiopharm S.A.

Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up

PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.

Deals Cancer

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.

China M & A

Merck KGaA Plumps For Reinvention To Refuel R&D

The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.

Business Strategies Oncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Other Names / Subsidiaries
    • H3 Pharma
    • Affinium Pharmaceuticals, Ltd.
UsernamePublicRestriction

Register